EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Paradoxical Activation of Entheseal Myeloid Cells by JAK1 and Tyk2 Inhibitors via Interleukin‐10 Antagonism

Sami Giryes iD, Chi Wong, Charlie Bridgewood, Mark Harland, Ala Altaie iD, Nicole McDermott, Kerem Abacar, Abhay Rao, Almas Khan, Tristan McMillan, Peter Loughenbury, Robert Dunsmuir und 3 weitere

Arthritis & Rheumatology · 2025

DOI: 10.1002/art.43210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Sami Giryes und 14 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, and B. Shine Rheumatology Institute, Rambam He…. Hauptthemen laut MEDLINE: TYK2 Kinase, Janus Kinase 1, Myeloid Cells, Interleukin-10. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

JAK inhibition (JAKi) is effective in seronegative spondyloarthropathy (SpA) spectrum disorders, but Tyk2 inhibition failed in SpA spectrum ulcerative colitis, and tofacitinib showed minimal benefit in Crohn disease, which highlights the complex role for JAK/STAT signaling in different inflammatory processes. In this study, we investigated whether JAKi might paradoxically activate entheseal innate immunity and aimed to identify the key regulatory cytokines involved in this process.

Methods

Spinal entheseal tissue was activated with Toll‐like receptor (TLR) agonists, including TLR4 and interleukin‐1 (IL‐1) family proteins, and entheseal T cells were activated with anti‐CD3/anti‐CD28 with IL‐23/IL‐1β. JAKi via upadacitinib (JAK1/JAK2), deucravacitinib (Tyk2), and ritlecitinib (JAK3) inhibition was evaluated using multiplex cytokine assays, intracellular flow, and bulk RNA sequencing (RNAseq) and cytokine blocking or stimulation.

Results

Following interferon γ stimulation, JAK1 inhibition blocked STAT1 phosphorylation in entheseal cells and strongly blocked activated entheseal T cell tumor necrosis factor α (TNFα), IL‐17A, and IL‐17F production. The opposite effect was evident in entheseal myeloid cell with exaggerated TLR4 and other adjuvant‐mediated cytokine production including IL‐23 (~10‐fold increase; P < 0.001) or TNFα (~10‐fold increase; P < 0.0001). This myeloid effect was induced by upadacitinib and deucravacitinib but not ritlecitinib, suggesting IL‐10R JAK1/Tyk2 signaling. Bulk RNAseq showed a multifaceted impact of JAKi on myeloid activation with strong M1 type monocyte polarization under TLR4 stimulation and JAK1 inhibition confirmed by flow cytometry. Direct IL‐10 inhibition recapitulated inflammatory cytokine elevations and IL‐10R agonist largely, but not completely, rescued this phenotype.

Conclusion

These findings help explain the emergent efficacy of Tyk2 blockade in SpA spectrum–related arthritis that is not IL‐10 dependent but indicates why such strategies may not be a panacea for SpA spectrum disorder–related intestinal inflammation. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TYK2 KinaseJanus Kinase 1Myeloid CellsInterleukin-10Janus Kinase InhibitorsHumansHeterocyclic Compounds, 3-RingImmunity, InnateT-LymphocytesInterleukin-17Signal TransductionCytokinesProtein Kinase InhibitorsToll-Like Receptor 4

Substanzen

TYK2 KinaseJanus Kinase 1Interleukin-10upadacitinibJanus Kinase InhibitorsTYK2 protein, humanHeterocyclic Compounds, 3-RingJAK1 protein, humanInterleukin-17Cytokines

Autor:innen und Institutionen

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, and B. Shine Rheumatology Institute, Rambam Healthcare Campus, Haifa, Israel.
  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom.
  • Leeds Biomedical Research Centre, Leeds Teaching Hospitals, National Institute for Health and Care Research, Leeds, United Kingdom.
  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds Biomedical Research Centre, Leeds Teaching Hospitals, National Institute for Health and Care Research, Leeds, United Kingdom.

ORCID-Profile: Sami Giryes, Ala Altaie

Förderung

  • AbbVie

Zitieren

APA

Giryes, S., Wong, C., Bridgewood, C., Harland, M., Altaie, A., McDermott, N., Abacar, K., Rao, A., Khan, A., McMillan, T., Loughenbury, P., Dunsmuir, R., Borse, V., Macleod, T., & McGonagle, D. (2025). Paradoxical Activation of Entheseal Myeloid Cells by JAK1 and Tyk2 Inhibitors via Interleukin‐10 Antagonism. Arthritis & Rheumatology. https://doi.org/10.1002/art.43210

Vancouver

Giryes S, Wong C, Bridgewood C, Harland M, Altaie A, McDermott N, et al. Paradoxical Activation of Entheseal Myeloid Cells by JAK1 and Tyk2 Inhibitors via Interleukin‐10 Antagonism. Arthritis & Rheumatology. 2025. doi:10.1002/art.43210

BibTeX
@article{Giryes2025,
  author = {Giryes, Sami and Wong, Chi and Bridgewood, Charlie and Harland, Mark and Altaie, Ala and McDermott, Nicole and Abacar, Kerem and Rao, Abhay and Khan, Almas and McMillan, Tristan and Loughenbury, Peter and Dunsmuir, Robert and Borse, Vishal and Macleod, Tom and McGonagle, Dennis},
  title = {Paradoxical Activation of Entheseal Myeloid Cells by JAK1 and Tyk2 Inhibitors via Interleukin‐10 Antagonism},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  doi = {10.1002/art.43210}
}
Kostenlos starten →